Результати пошуку - Allan Hebbert
- Показ 1 - 2 результатів із 2
-
1
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with <i>MTAP</i>-Deleted Cancer за авторством Lars D. Engstrom, Ruth Aranda, Laura Waters, Krystal Moya, Vickie Bowcut, Laura Vegar, David Trinh, Allan Hebbert, Christopher R. Smith, Svitlana Kulyk, J. David Lawson, Leo He, Laura D. Hover, Julio Fernandez-Banet, Jill Hallin, Darin Vanderpool, David M. Briere, Alice Blaj, Matthew A. Marx, Jordi Rodón, Michael Offin, Kathryn C. Arbour, Melissa L. Johnson, David J. Kwiatkowski, Pasi A. Jänne, Candace L. Haddox, Kyriakos P. Papadopoulos, Jason T. Henry, Konstantinos Leventakos, James G. Christensen, Ronald Shazer, Peter Olson
Опубліковано 2023Artigo -
2
The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading за авторством Niranjan Sudhakar, Larry Yan, Fadia Qiryaqos, Lars D. Engstrom, Jade Laguer, Andrew Calinisan, Allan Hebbert, Laura Waters, Krystal Moya, Vickie Bowcut, Laura Vegar, John M. Ketcham, Anthony Ivetac, Christopher R. Smith, J. David Lawson, Lisa Rahbæk, Jeffrey Clarine, Natalie Nguyen, Barbara Saechao, Cody Parker, A. J. ELLIOTT, Darin Vanderpool, Leo He, Laura D. Hover, Julio Fernandez-Banet, Sílvia Coma, Jonathan A. Pachter, Jill Hallin, Matthew A. Marx, David M. Briere, James G. Christensen, Peter Olson, Jacob R. Haling, Shilpi Khare
Опубліковано 2024Artigo
Інструменти для пошуку:
Пов'язані теми
Biology
Cancer
Cancer research
Gene
Biochemistry
Colorectal cancer
DNA repair
Druggability
Genetics
Guanine nucleotide exchange factor
Internal medicine
KRAS
Kinase
MAPK/ERK pathway
MEK inhibitor
Medicine
Melanoma
Methylation
Methyltransferase
Protein arginine methyltransferase 5
Selumetinib
Signal transduction
Synthetic lethality